MedPath

Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

Shanghai Haiyan Pharmaceutical Technology Co., Ltd. logo
🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

14

Active:4
Completed:5

Trial Phases

3 Phases

Phase 1:8
Phase 2:3
Phase 3:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials

Phase 1
8 (57.1%)
Phase 2
3 (21.4%)
Phase 3
3 (21.4%)

Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder

Phase 3
Recruiting
Conditions
Insomnia Disorder
Interventions
First Posted Date
2025-05-16
Last Posted Date
2025-07-15
Lead Sponsor
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Target Recruit Count
60
Registration Number
NCT06975514
Locations
🇨🇳

Peking University People's Hospital, Beijing, China

🇨🇳

ChengDu Second People's Hospital, Chengdu, China

🇨🇳

ChongQing Traditional Chinese Medicine Hospital, ChongQing, China

and more 13 locations

A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Orthopedic Surgery

Phase 2
Not yet recruiting
Conditions
Pain
Interventions
First Posted Date
2025-03-30
Last Posted Date
2025-03-30
Lead Sponsor
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Target Recruit Count
150
Registration Number
NCT06901830
Locations
🇨🇳

The First Hospital of Jilin University, Ch'ang-ch'un, China

🇨🇳

The Third Xiangya Hospital of Central South University, Changsha, China

🇨🇳

Chengdu Second People's Hospital, Chengdu, China

and more 18 locations

A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal Surgery

Phase 3
Not yet recruiting
Conditions
Pain
First Posted Date
2025-03-24
Last Posted Date
2025-03-24
Lead Sponsor
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Target Recruit Count
560
Registration Number
NCT06890533
Locations
🇨🇳

Cangzhou Central Hospital, Cangzhou, China

🇨🇳

Cangzhou People's Hospital, Cangzhou, China

🇨🇳

The First Hospital of Jilin University, Ch'ang-ch'un, China

and more 46 locations

PK/PD Study of YZJ-1139

Phase 1
Completed
Conditions
Insomnia
Interventions
First Posted Date
2024-11-12
Last Posted Date
2024-11-12
Lead Sponsor
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Target Recruit Count
20
Registration Number
NCT06685341
Locations
🇨🇳

Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Safety and Efficacy Study of YZJ-1139 in Primary Chronic Insomnia Disorder

Phase 2
Completed
Conditions
Insomnia Disorder
Interventions
Drug: YZJ-1139 10mg
Drug: YZJ-1139 20mg
Drug: YZJ-1139 40mg
Drug: YZJ-1139 60mg
Drug: Placebo
First Posted Date
2024-11-08
Last Posted Date
2024-11-08
Lead Sponsor
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Target Recruit Count
300
Registration Number
NCT06680505
Locations
🇨🇳

Beijing HuiLongGuan Hospital, Beijing, China

🇨🇳

Peking University People's Hospital, Beijing, China

🇨🇳

Xuanwu Hospital, Capital Medical University, Beijing, China

and more 30 locations
  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.